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Abstract
A 36-year-old woman presents to hospital peri-arrest with hypertension, sustained loss of
consciousness following a tonic clonic seizure and a micropathic haemolytic anaemia on blood film.
After initial resuscitation, more specialised treatment was instigated as the diagnosis became clearer
but all was not as it first seemed. This case demonstrates the importance of re-examination, especially
in the critically ill, in conjunction with unusual laboratory tests in order to eventually reach a rare
diagnosis of a rare presentation.
Case presentation
A previously healthy 36-year-old Caucasian female was
brought by ambulance to a South London Accident and
Emergency department having collapsed at home. She was
transferred to the General Intensive Care Unit soon after
arrival at the hospital.
A collateral history was sought from the patient’s husband.
S h eh a da3d a yh i s t o r yo fd i a r r h o e aa n dv o m i t i n gb u t
otherwise no headache, photophobia, fevers or recent travel.
There was no past medical history and he could not
remember any unusual complaints or prior symptoms. He
had witnessed abnormal twitching of his wife’s right hand
and arm, which then progressed to a tonic-clonic seizure.
Paramedicswerecalledandfoundthepatientobtundedwith
a Glasgow Coma Scale (GCS) score of 3/15 (E1, M1, V1).
On arrival at the Resuscitation room, her heart rate was
130 bpm, with a blood pressure 240/120 mmHg. She had
been intubated with a cuffed endotracheal tube by the
attending paramedics and was mechanically ventilated
with an inspired FiO2 of 0.4. Initial examination revealed
mild jaundice but no hepatosplenomegaly or lymphade-
nopathy. She was bleeding from her right nostril but there
was no rash or obvious bruising. Her lung fields were clear
and heart sounds normal. A urine dipstick revealed the
presence of blood cells (+++) and protein (+++) and an
electrocardiogram showed t-wave inversion in chest leads
V1-5 as the only abnormality. Chest x-ray demonstrated
generalised interstitial shadowing consistent with pul-
monary oedema. Arterial blood gas on admission showed
pH 6.74, lactate 18 and a base deficit of 23.2. Empirical
therapy for suspected meningitis was started. One gram of
phenytoin was given intravenously.
The patient was transferred the General Intensive Care
Unit. Once stable following fluid resuscitation she under-
went a computed tomography scan of her brain. This
Page 1 of 5
(page number not for citation purposes)showed no evidence of acute cerebral bleed, space
occupying lesion or features of raised intracranial pressure.
Concurrently her formal laboratory blood tests became
available (Table 1).
Lumbar puncture was not performed owing to the low
platelet count. The patient’s blood film confirmed a
microangiopathic haemolytic anaemia (MAHA, an example
of which is shown in Figure 1) with anisopoikilocytosis,
marked RBC fragmentation and crenation (as well as
reticulocytes, spherocytes,polychromasia andneutrophilia).
Two hours into the admission following advice from our
haematology colleagues, the working diagnosis was either
haemolytic-uraemic syndrome (HUS) or thrombotic
thrombocytopoenic purpura (TTP). Six hours after admis-
sion the patient was administered with 500 mg methyl-
prednisolone and underwent plasmaphoresis against
Fresh Frozen Plasma.
The next morning the working diagnosis was refined as
follows: verotoxin producing E.coli (VTEC) + HUS with
MAHA + Hypertension induced encephalopathy and
concurrent Acute Kidney Injury. The hypertension was
managed with intravenous and oral anti-hypertensives.
The patient received a second cycle of plasma exchange.
Repeat clinical examination demonstrated a small smooth
liver edge and an abdominal ultrasound scan showed no
obvious intrahepatic pathology or biliary tree and urinary
system dilation or blockage. More subtle clinical findings
included tight hyperpigmented skin of fingers and hands to
the wrist bilaterallyand a V shapedarea of thickened skinto
the praecordium, sclerodactyly of the hands, but not the
feet, and telangiectasiae to the face and neck. There were no
digital ulcers or signsof calcinosisand followingreviewand
consultation with our rheumatology and nephrology
colleagues we revised the working diagnosis to scleroderma
renal crisis (SRC) precipitated by diarrhoea and vomiting.
With this in mind further collateral history was sought
from the husband who described his wife as stoical.
However, he mentioned she had complained of ‘painful
hands’ over the last two months but there was no change
in finger colour. The patient’s father has hyperpigmented
skin to his elbows and the patient’s mother suffered with
diabetes mellitus.
On day four she became anuric. A chest x-ray demon-
strated pulmonary oedema and bilateral pleural effusions
and continuous veno-venous haemofiltration (CVVHF)
was commenced. Echocardiogram demonstrated a small
pericardial effusion which did not cause haemodynamic
compromise.
The results of autoimmune studies, which were taken on
admission prior to plasma exchange, also became avail-
able on day four and are shown in Table 2.
In view of the revised diagnosis the patient was
transferred to a Regional Centre with a special interest
in scleroderma. Further tests and investigations were
performed (Table 3). She was discharged home on day
28 but continues to require renal replacement therapy
Table 1. Admission blood test results
Haemoglobin 6.6 g/dL (12.0-16.0) Sodium 137 mmol/L (135-145)
Platelets 32 10
9/L (150-450) Potassium 4.3 mmol/L (3.5-4.7)
White blood cells 24.7 10
9/L (4.0-11.0) Urea 13.6 mmol/L (2.5-8.0)
Neutrophils 15.9 10
9/L (1.7-8.0) Creatinine 266 µmol/L (60-110)
INR 1.5 (0.8-1.1) LDH 1164 U/L (0-175)
APTT ratio 1.68 (0.85-1.15) Glucose 13.7 mmol/L (3.0-6.0)
Thrombin Time 17 secs (11-16) Bilirubin 40 µmol/L (0-17)
Fibrinogen 1.8 g/L (2-4) ALT 30 U/L (0-40)
D-dimer 2.75 mg/L (0-0.3) ALP 64 U/L (35-120)
CRP 14.8 mg/L (0-10) Albumin 25 g/l (35-48)
Bicarbonate 17 mmol/L (22-32) Gamma GT 13 U/L (0-38)
Phosphate 3.26 mmol/L (0.75-1.5) CK 274 µmol/L (30-210)
Figure 1. Blood film of MAHA (reproduced with permission
from commons.wikimedia.org/wiki/Image:
DIC_With_Microangipahic_Hemolytic_Anemia.jpg).
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Dialysis (CAPD). Her hypertension is well controlled
with Enalapril, Irbesartan and Furosemide. Six months
following presentation, she is back at work on a part time
basis. The final diagnosis was Diffuse Cutaneous
systemic sclerosis / scleroderma with microangiopathic
haemolytic anaemia and renal crisis with persistent
hypertension.
Discussion
Microangiopathic haemolytic anaemia (MAHA) is defined
as haemolysis of erythrocytes in capillaries, leading to
anaemia. It is a rare disease.
Abnormal factors (including high shear stress) lead to
vascular endothelial disruption of capillaries, deposition
of Fibrin mesh and platelet aggregation. This causes lysis
of the red blood cells (RBCs), formation of schistocytes
and RBC fragments with consumption of platelets. The
resultant clinical picture is: anaemia (typically haemaglo-
bin lower than 8 g/dL), thrombocytopoenia (platelet
count < 140 × 10
9/L) with schistocytes and helmet cells
on blood film. Although not performed in our patient, a
Coombs test is usually negative.
The main causes of a MAHA are: Haemolytic Uraemic
Syndrome (HUS, types I - typical and II - atypical),
Thrombotic Thrombocytopoenic Purpura (TTP) and Dis-
seminated Intravascular Coagulation (DIC). There
are however other causes of a MAHA which include, but
are not limited to, malignant hypertension (hence the
association with scleroderma renal crisis). These are
summarised in Table 4 below.
Initial management
Our patient was transferred rapidly to the Intensive Care
Department having come through the Emergency depart-
ment. She was in extremis and initial management goals
were life saving resuscitation and organ support with
correction of her acidosis.
We included empirical antibiotics for meningitis since
differential diagnosis included sepsis with neurological
involvement.
The blood results revealed thrombocytopenic anaemiawith
RBC fragments on blood film. The diagnosis of TTP/HUS
was reached with the assistance of our haematology
colleagues. Despite the abnormal clotting screen it was felt
that the findings of the blood film in conjunction with the
clinical picture favoured the diagnosis reached. Standard
treatment for this is plasmaphoresis. If left untreated, HUS/
TTPfollowsaprogressivecourseleadingtoirreversiblerenal
failure and death. Plasmaphoresis reverses platelet con-
sumption responsible for thrombus formation and the
sequelae that characterise this condition [1] and may be
Table 3. Results from tests performed after transfer to the specialist
scleroderma centre
ANA Positive
>1/1000 fine speckle pattern
>1/100 ++ nucleolar
RNA Polymerase antibody Positive
SCL-70 Negative
Rheumatoid factor Negative
ENA screen Negative
Double stranded DNA antibodies 5
C3 105 mg/dL
C4 21 mg/dL
HB SAg, EBV IgG, CMV IgG,
HSV1 IgG, HSV2 IgG, VZV IgG
All positive
Table 2. Immunological blood test results
C3 0.5 g/L (0.75-1.65)
C4 0.08 g/L (0.14-0.54)
ADAMTS-13 20% (not pathogenic)
ANA Positive (speckled pattern,
chromosome negative)
ANCA negative
Antiphospholipid screen normal
IgG cardiolipin antibodies 0.8 (normal)
IgM cardiolipin antibodies 1.7 (normal)
Anti SS-A, Anti SS-B, Anti SM,
Anti RNP, Anticardiolipin IgG
negative
HBV SAg, HCV antibody, CMV IgM negative
Table 4. Summary of the causes of MAHA
Features common to all
causes of MAHA
Anaemia (Hb < 8 g/dL)
Thrombocytopoenia (platelets < 140 x 10
9/L)
Red Blood Cell fragments, Schistocytes and
helmet cells on blood film
Negative Coombs test (IgG autoantibodies to
individual’s red blood cells)
Possible multi-system involvement
HUS type I
(Shiga-like / Verotoxin
associated)
Associated with Verotoxin (Shiga-like) E. coli
O157 infection
Prodrome of diarrhoea, often bloody, 3-5
days before onset
Typically affects children < 5 yrs
Commonly acute renal failure
HUS type II
(Non Shiga-like)
Not thought to be associated with diarrhoea
TTP Neurological symptoms predominant
Acute kidney injury
Pyrexia
Disseminated Intravas-
cular Coagulation
Activation of the intravascular clotting
cascade
Consumption of clotting factors and
fibrinogen
Consumption of platelets
Raised INR, PT, APTTR
Other causes Aortic Stenosis / replacement valve
Scleroderma renal crisis
Severe glomerulonephritis
malignant hypertension,
pregnancy associated microangiopathy
(incl. pre-eclampsia, HELLP syndrome)
infective (shigella, TB, E. Coli)
Drug related (e.g. Heparin - Heparin Induced
Thrombocytopoenia (HIT))
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As a result, the mortality rate has dropped from previous
rates of 90% [3] and presently it is mostly curable.
In TTP specifically, a deficiency of, or autoantibodies to,
ADAMTS-13 can lead to platelet aggregation and MAHA.
In these patients, plasma exchange helps remove the
acquired autoantibody, as well as large vWF multimers,
helping prevent further thrombosis [3]. Steroids, such as
methylprednisolone, may reduce the production of auto-
antibodies. Our patient received 500mg of methyl
prednisolone on this basis. Normal levels of ADAMTS-
13 are activities of 68-128%. However, studies show that
parents of TTP patients with levels of 6-20% are usually
asymptomatic and levels as low as 5-10% are still enough
to prevent micro thrombi [4]. With a level of 20%, it was
felt that our patient did not have TTP.
Our patient contemporaneously suffered with persistent
hypertension which was initially managed with a prosta-
cyclin infusion and oral captopril. Glomerular involve-
ment in HUS/TTP can lead to cortical necrosis (secondary
to glomerular thrombotic microangiopathy). Arterioles
and interlobular arteries are affected with intimal oedema,
luminal narrowing and thrombosis with necrosis of the
arteriolar wall. The glomeruli appear small and shrunken,
with splitting of the capillary wall and interruption of the
basement membrane, which is the lesion thought to be
responsible for severe hypertension [5]. Anti-hypertensive
treatment was titrated to 10 ng/kg/min iloprost, 100 mg
tds captopril and an infusion of labetalol. Her acute renal
failure was treated with continuous veno-venous haemo-
filtration (CVVHF).
‘Secondary survey’ / review
Our initial focus was providing life-saving treatment but
hyperpigmentation, sclerodactyly, thickened skin on the
praecordium and telangectasiae were all notedon repeated
examination once our patient was stable. Further collateral
history revealed a 2-month history of painful hands and a
family history of autoimmune disease.
The diagnosis of scleroderma renal crisis (SRC) becomes
more likely and this was confirmed by the availability of
additional investigations taken on admission over the
following days.
Scleroderma renal crisis
A comprehensive review of Scleroderma renal crisis
discussed the common presenting features of SRC [6].
Table 5 conveniently summarises these features (repro-
duced with permission).
As can be seen from the case history, our patient suffered
from all of the features listed, with the exception of
retinopathy. SRC is differentiated from TTP in systemic
sclerosis (SSc) with some difficulty but can be made
primarily on the presence or absence of haemorrhage,
fever and hypertension [7]. A concurrent diagnosis of
diffuse cutaneous systemic sclerosis (dcSSc) was also made
and this was the first presentation of the disease. The
diagnosis of SSc is primarily made on clinical grounds:
sclerodactyly, telangectasiae, hyperpigmented skin of
distal arms/hands and thickened skin to the praecordium.
Additionally, the positive ANA (>1/1000 fine speckle
pattern, > 1/100 ++ nucleolar) and RNA polymerase is
strongly associated with the diagnosis of SRC and SSc [8].
The patient’s Scl-70 was negative, which is a sensitive and
highly specific marker for systemic sclerosis, yet in the
cases of SRC was present in only 17% patients [6], and in
this instance does not rule out SSc.
The pathogenesis of SRC is thought to be as a result of
capillary endothelial activation, releasing multiple vasoac-
tive substances, some of which are thought to be
pathogenic [9]. These may work in a similar way as to
that of Verotoxin in HUS. Acute loss of renal function
reflects the degree of vascular damage, which is indepen-
dent of the blood pressure. Acute renal tissue change was
also associated with a poorer prognosis of renal function
[6]. At the time of writing the results of our patients’ renal
biopsy are unknown.
On review of our patient, it was concluded that
immunosuppressive therapy was not required immedi-
ately: SRC is a vascular pathology (as described above)
that requires medical treatment in the form of ACE
inhibition. This constitutes renal saving therapy and the
immunosuppressive medications were stopped. In addi-
tion, careful avoidance of volume depletion (i.e. with
CVVHF) was needed, due to the high peripheral vascular
resistance and rapid onset of hypertension with
hypovolaemia.
As a result, new treatment goals were sustained lower
blood pressure, renal supportive therapy in the form of
CVVHF and continued management of fluid-balance to
Table 5. Renal crisis classification
1. New onset hypertension (>150/85 mmHg)
2. Decrease in eGFR (>30%)
Plus any of the following corroborative features:
MAHA on blood film
New onset RBCs in urine (excluding other causes)
Flash pulmonary oedema
Retinopathy typical of acute hypertensive crisis
Oliguria or anuria
Renal biopsy showing characteristic changes (accumulation of mucin
in interlobular arteries - indistinguishable from accelerated
hypertension - and fibrinoid calcinosis of arterioles)
Modified slightly from original and kindly reprinted with permission [11].
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pulmonary oedema.
Mycophenolate Mofetil (MMF) was commenced to limit
the fibrotic complications in relation to cutaneous
and organ involvement [10] in dcSSc. MMF is an
immunomodulating medication, specifically an inositol
monophosphate dehydrogenase (IMPDH) antagonist, an
enzyme essential for the de novo guanosine nucleotide
synthesis. It is more commonly used to prevent transplant
graft rejection and in the treatment of lupus.
We have already discussed, in retrospect, there is a strong
correlation withourpatient’spresentingfeatures andthose
documented in the literature for scleroderma renal crisis.
Our patient, with anti-RNA polymerase antibody and early
dcSSC was at the highest risk for developing SRC [6].
Mortality and prognosis
There is a significant mortality associated with SRC.
Survival is listed as 82% at 1 year and 59% at 5 years
[6]. The index of chronic kidney damage did not correlate
with prognosis in SRC, which is contrary to a wide range of
renal diseases. This could be a result of the vascular
pathogenesis. Patients who needed dialysis temporarily
had the best prognosis and those with higher BP and
younger age (as in our patient) were associated with a
better renal outcome [6]. Unfortunately the overall
prognosis at this time remains poor.
Conclusion
This case is of particular interest to Intensive Care, General
Medical, Renal and Haematology physicians. It is a rare
presentation of a rare condition (MAHA), rendering the
patient critically ill. Initially believed to be secondary to a
verotoxin producing E. coli infection causing HUS/TTP, it
was, on reflection of the complete clinical picture, a
scleroderma renal crisis. The ultimate diagnosis was one of
diffuse cutaneous systemic sclerosis (DcSSc). Our patient’s
management has been demonstrably correct and was
altered appropriately as new evidence came to light and
involved many different specialist teams. However, this
case also underlines the importance of careful and
repeated examination, with regular review of clinical
signs, even when the patient is critically ill. This is
highlighted when complex treatments such as plasma-
pheresis may require early transfer to another institution.
These basic skills of practicing medicine will lead to the
correct diagnosis even in rare cases and in the face of life
threatening physiology.
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